Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219539 | 0.86 | CHRM2 (0.44) | CHRM2CHRM4BPTFDPP4PREP | |
| SCHEMBL5222222 | 0.86 | BPTF (0.59) | CHRM2CHRM4BPTFDPP4PREP | |
| SCHEMBL2941456 | 0.80 | BPTF (0.47) | CHRM2BPTFNOTUMABL1FFAR4 | |
| SCHEMBL31411844 | 0.77 | FFAR4 (0.51) | BPTFDPP4NOTUMFFAR4 | |
| SCHEMBL5219506 | 0.76 | SSTR2 (0.44) | CHRM2CHRM4DPP4PREPDPP8 | |
| SCHEMBL18825904 | 0.73 | DRD2 (0.58) | CHRM2CHRM4GRM5DRD2DRD3 | |
| SCHEMBL27714650 | 0.73 | NOTUM (0.55) | BPTFNOTUMDRD2DRD3 | |
| SCHEMBL14587274 | 0.73 | DPP4 (0.69) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL18825950 | 0.72 | FADS1 (0.41) | CHRM2CHRM4DPP4PREPDPP8 | |
| Hydrochloric Acid SCHEMBL7236978 | 0.72 | DRD2 (0.57) | CHRM2CHRM4GRM5DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399433-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7183290-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | CHRM2 4861/4885CHRM4 4638/4885BPTF 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.